A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
Takeda Development Center Americas (TDCA)
Cita
A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease. (VedolizumabSC-3004). Takeda Development Center Americas (TDCA). 2026IP:ESTER DONAT ALIAGA.
Portal de investigación